This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Denkert, C. Articles by Hauptmann, S. Search for Related Content PubMed PubMed Citation Articles by Denkert, C. Articles by Hauptmann, S.

Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression

¹Institute of Pathology and ²Department of Gynecology and Obstetrics, Charité Hospital, Berlin, Germany; ³Institute of Public Health–Epidemiology Unit, Technical University of Berlin, Germany; and ⁴Institute of Pathology, Martin-Luther University Halle-Wittenberg, Halle, Germany

The human embryonic-lethal abnormal vision-like protein HuR is involved in the regulation of mRNA turnover and serves as a shuttling protein between the nucleus and the cytoplasm that stabilizes mRNAs containing adenine- and uridine-rich elements in their 3' untranslated region. We have shown recently that expression of cyclooxygenase (COX)-2 is related to poor prognosis in ovarian carcinoma. Other studies have shown that the COX-2 mRNA contains an adenine- and uridine-rich element and is stabilized by HuR. In this study, we investigated the expression and cellular distribution of HuR in 83 primary ovarian carcinomas, 16 borderline tumors of the ovary, 3 normal ovaries, and 9 ovarian carcinoma cell lines. Expression of HuR was detected in all cell lines on the mRNA and protein level and showed a predominantly nuclear staining in OVCAR-3 cells by confocal microscopy. In an immunohistochemical evaluation of human ovarian carcinomas, HuR showed a nuclear expression in 81% of tumors. In addition, a cytoplasmic expression of HuR was observed in a subgroup of 45% of ovarian carcinomas. Nuclear as well as cytoplasmic expression of HuR was significantly increased in ovarian carcinomas compared with borderline tumors or normal ovaries. In univariate analysis, a significant association between cytoplasmic HuR expression and increased COX-2 expression (P = 0.025) as well as between histological grade (P = 0.008) and mitotic activity (P = 0.002) was observed, although nuclear expression of HuR was not correlated with COX-2 expression or other clinicopathological parameters. In Kaplan-Meier survival analysis, increased cytoplasmic expression of HuR was a significant prognostic indicator for progression-free survival (P = 0.03) as well as overall survival (P = 0.007). In multivariate analysis using the Cox regression model, cytoplasmic expression of HuR was an independent prognostic parameter for reduced overall survival with a relative risk of 2.62 (95% confidence interval, 1.32–5.19). Our results suggest that there is a dysregulation of cellular distribution of the mRNA stability factor HuR in a subset of invasive ovarian carcinomas. This dysregulation appears to result in an increased expression of COX-2, an increased proliferative rate, and may lead to a reduced survival time. Additional studies are required to analyze the downstream effects of increased cytoplasmic expression of HuR. In addition, it would be interesting to investigate the prognostic role of increased cytoplasmic expression of HuR in prospective studies.

This article has been cited by other articles:

				R. A. Oyesanya, Z. P. Lee, J. Wu, J. Chen, Y. Song, A. Mukherjee, P. Dent, T. Kordula, H. Zhou, and X. Fang Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells FASEB J, August 1, 2008; 22(8): 2639 - 2651. [Abstract] [Full Text] [PDF]

				V. R. Moulton, V. C. Kyttaris, Y.-T. Juang, B. Chowdhury, and G. C. Tsokos The RNA-stabilizing Protein HuR Regulates the Expression of {zeta} Chain of the Human T Cell Receptor-associated CD3 Complex J. Biol. Chem., July 18, 2008; 283(29): 20037 - 20044. [Abstract] [Full Text] [PDF]

				C. L. Kanies, J. J. Smith, C. Kis, C. Schmidt, S. Levy, K. S.A. Khabar, J. Morrow, N. Deane, D. A. Dixon, and R. D. Beauchamp Oncogenic Ras and Transforming Growth Factor-{beta} Synergistically Regulate AU-Rich Element-Containing mRNAs during Epithelial to Mesenchymal Transition Mol. Cancer Res., July 1, 2008; 6(7): 1124 - 1136. [Abstract] [Full Text] [PDF]

				M. Heinonen, R. Fagerholm, K. Aaltonen, O. Kilpivaara, K. Aittomaki, C. Blomqvist, P. Heikkila, C. Haglund, H. Nevanlinna, and A. Ristimaki Prognostic Role of HuR in Hereditary Breast Cancer Clin. Cancer Res., December 1, 2007; 13(23): 6959 - 6963. [Abstract] [Full Text] [PDF]

				S. C. Jeyaraj, D. Dakhlallah, S. R. Hill, and B. S. Lee Expression and distribution of HuR during ATP depletion and recovery in proximal tubule cells Am J Physiol Renal Physiol, December 1, 2006; 291(6): F1255 - F1263. [Abstract] [Full Text] [PDF]

				K. Leandersson, K. Riesbeck, and T. Andersson Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells Nucleic Acids Res., September 1, 2006; 34(14): 3988 - 3999. [Abstract] [Full Text] [PDF]

				X. Guo and R. S. Hartley HuR Contributes to Cyclin E1 Deregulation in MCF-7 Breast Cancer Cells Cancer Res., August 15, 2006; 66(16): 7948 - 7956. [Abstract] [Full Text] [PDF]

				P. W. Szlosarek, M. J. Grimshaw, H. Kulbe, J. L. Wilson, G. D. Wilbanks, F. Burke, and F. R. Balkwill Expression and regulation of tumor necrosis factor {alpha} in normal and malignant ovarian epithelium. Mol. Cancer Ther., February 1, 2006; 5(2): 382 - 390. [Abstract] [Full Text] [PDF]

				J. Mrena, J.-P. Wiksten, A. Thiel, A. Kokkola, L. Pohjola, J. Lundin, S. Nordling, A. Ristimaki, and C. Haglund Cyclooxygenase-2 Is an Independent Prognostic Factor in Gastric Cancer and Its Expression Is Regulated by the Messenger RNA Stability Factor HuR Clin. Cancer Res., October 15, 2005; 11(20): 7362 - 7368. [Abstract] [Full Text] [PDF]

				Y. Z. Xu, S. Di Marco, I. Gallouzi, M. Rola-Pleszczynski, and D. Radzioch RNA-Binding Protein HuR Is Required for Stabilization of SLC11A1 mRNA and SLC11A1 Protein Expression Mol. Cell. Biol., September 15, 2005; 25(18): 8139 - 8149. [Abstract] [Full Text] [PDF]

				T. Daikoku, D. Wang, S. Tranguch, J. D. Morrow, S. Orsulic, R. N. DuBois, and S. K. Dey Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer Cancer Res., May 1, 2005; 65(9): 3735 - 3744. [Abstract] [Full Text] [PDF]

				M. Heinonen, P. Bono, K. Narko, S.-H. Chang, J. Lundin, H. Joensuu, H. Furneaux, T. Hla, C. Haglund, and A. Ristimaki Cytoplasmic HuR Expression Is a Prognostic Factor in Invasive Ductal Breast Carcinoma Cancer Res., March 15, 2005; 65(6): 2157 - 2161. [Abstract] [Full Text] [PDF]

				C. Denkert, W. Weichert, K.-J. Winzer, B.-M. Muller, A. Noske, S. Niesporek, G. Kristiansen, H. Guski, M. Dietel, and S. Hauptmann Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma Clin. Cancer Res., August 15, 2004; 10(16): 5580 - 5586. [Abstract] [Full Text] [PDF]

				F. Spinella, L. Rosano, V. Di Castro, M. R. Nicotra, P. G. Natali, and A. Bagnato Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells Clin. Cancer Res., July 15, 2004; 10(14): 4670 - 4679. [Abstract] [Full Text] [PDF]